RU2011140858A - Конъюгаты гаптен-носитель, содержащие в качестве носителя бактериальные токсины, обладающие сигнальным пептидом, и их применение в иммуногенных композициях - Google Patents

Конъюгаты гаптен-носитель, содержащие в качестве носителя бактериальные токсины, обладающие сигнальным пептидом, и их применение в иммуногенных композициях Download PDF

Info

Publication number
RU2011140858A
RU2011140858A RU2011140858/15A RU2011140858A RU2011140858A RU 2011140858 A RU2011140858 A RU 2011140858A RU 2011140858/15 A RU2011140858/15 A RU 2011140858/15A RU 2011140858 A RU2011140858 A RU 2011140858A RU 2011140858 A RU2011140858 A RU 2011140858A
Authority
RU
Russia
Prior art keywords
immunogenic composition
nicotine
gly
immune response
signal peptide
Prior art date
Application number
RU2011140858/15A
Other languages
English (en)
Russian (ru)
Inventor
Уилльям ХЕНРИ
Original Assignee
Уилльям ХЕНРИ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Уилльям ХЕНРИ filed Critical Уилльям ХЕНРИ
Publication of RU2011140858A publication Critical patent/RU2011140858A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Addiction (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2011140858/15A 2009-03-09 2010-03-09 Конъюгаты гаптен-носитель, содержащие в качестве носителя бактериальные токсины, обладающие сигнальным пептидом, и их применение в иммуногенных композициях RU2011140858A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20962909P 2009-03-09 2009-03-09
US61/209,629 2009-03-09
PCT/EP2010/052997 WO2010103017A2 (en) 2009-03-09 2010-03-09 Hapten-carrier conjugates with bacterial toxins having a signal peptide as carrier and their use in immunogenic compositions

Publications (1)

Publication Number Publication Date
RU2011140858A true RU2011140858A (ru) 2013-04-20

Family

ID=42555592

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2011140858/15A RU2011140858A (ru) 2009-03-09 2010-03-09 Конъюгаты гаптен-носитель, содержащие в качестве носителя бактериальные токсины, обладающие сигнальным пептидом, и их применение в иммуногенных композициях

Country Status (9)

Country Link
US (1) US20120100171A1 (enExample)
EP (1) EP2405943A2 (enExample)
JP (1) JP2012519724A (enExample)
KR (1) KR20120022760A (enExample)
CN (1) CN102427828A (enExample)
CA (1) CA2754592A1 (enExample)
MX (1) MX2011009359A (enExample)
RU (1) RU2011140858A (enExample)
WO (1) WO2010103017A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2730328C (en) * 2008-09-03 2015-03-31 Board Of Trustees Of Michigan State University Immunogenic escherichia coli heat stable enterotoxin
ES2732815T3 (es) 2009-05-22 2019-11-26 Genocea Biosciences Inc Vacunas frente al virus del herpes simple de tipo 2: composiciones y métodos para provocar una respuesta inmunitaria
WO2011041483A2 (en) * 2009-09-30 2011-04-07 Toxcure, Inc. Use of botulinum neurotoxin to treat substance addictions
EP2643014A4 (en) 2010-11-24 2015-11-11 Genocea Biosciences Inc HERPES SIMPLEX TYPE 2 VIRUS VACCINES: COMPOSITIONS AND METHODS FOR STIMULATING AN IMMUNE RESPONSE
US10160789B2 (en) 2011-03-14 2018-12-25 University Of Louisville Research Foundation, Inc. Polypeptides having immunoactivating activity and methods of producing the same
US10758605B2 (en) 2015-06-29 2020-09-01 University Of Louisville Research Foundation, Inc. Compositions and methods for treating cancer and promoting wound healing
WO2018064232A1 (en) 2016-09-28 2018-04-05 Genocea Biosciences, Inc. Methods and compositions for treating herpes
US20210277071A1 (en) * 2016-09-29 2021-09-09 Ipsen Biopharm Limited Hybrid neurotoxins
CN113825984B (zh) * 2019-05-20 2024-08-13 美国西门子医学诊断股份有限公司 用于检测免疫测定中由多半抗原试剂的不完全递送引起的异常结果的方法
EP3993836A1 (en) * 2019-07-03 2022-05-11 Intervet International B.V. Conjugated deoxynivalenol to protect against mycotoxicosis
US12343375B2 (en) 2021-02-09 2025-07-01 University Of Louisville Research Foundation, Inc. Spray dried formulation of a cholera toxin B subunit variant

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171568A (en) 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
US4883761A (en) 1986-03-25 1989-11-28 The United States Of America As Represented By The Department Of Health And Human Services Pertussis toxin gene: cloning and expression of protective antigen
JP2661044B2 (ja) 1986-06-17 1997-10-08 カイロン コーポレイション 肝炎δの診断薬およびワクチン
HU216017B (hu) 1987-11-18 1999-04-28 Chiron Corp. Eljárás HCV-1 polipeptidek, HCV-1 polinukleotidok, rekombináns vektorok és gazdasejtek, valamint immunesszé kit, hepatitis C vírusfertőzés elleni vakcinák, a fertőzés kimutatására szolgáló diagnosztikumok előállítására, és immunvizsgálati és vírustenyészt
JP2656995B2 (ja) 1989-03-17 1997-09-24 カイロン コーポレイション Ｎａｎｂｖの診断用薬
MC2188A1 (fr) 1989-05-18 1992-09-16 Chiron Corp Diagnostic du nanbv:polynucleotides permettant de depister le virus de l'hepatite c
US5773003A (en) 1995-03-31 1998-06-30 Immulogic, Inc. Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
US5876727A (en) 1995-03-31 1999-03-02 Immulogic Pharmaceutical Corporation Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
US20020032316A1 (en) 1995-03-31 2002-03-14 Cantab Pharmaceuticals Research Limited Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
FR2768747B1 (fr) 1997-09-19 2000-12-01 Pasteur Institut Acides nucleiques, cellules recombinantes, et procede de preparation de compositions immunogenes
CN1231586C (zh) * 2003-04-15 2005-12-14 中国科学院微生物研究所 一种多形汉逊酵母表达重组霍乱毒素b亚单位基因及其应用
GB0325494D0 (en) 2003-10-31 2003-12-03 Sbl Vaccin Ab Expression system

Also Published As

Publication number Publication date
CA2754592A1 (en) 2010-09-16
KR20120022760A (ko) 2012-03-12
JP2012519724A (ja) 2012-08-30
US20120100171A1 (en) 2012-04-26
WO2010103017A2 (en) 2010-09-16
CN102427828A (zh) 2012-04-25
MX2011009359A (es) 2011-12-16
EP2405943A2 (en) 2012-01-18
WO2010103017A3 (en) 2010-12-02

Similar Documents

Publication Publication Date Title
RU2011140858A (ru) Конъюгаты гаптен-носитель, содержащие в качестве носителя бактериальные токсины, обладающие сигнальным пептидом, и их применение в иммуногенных композициях
Tochikubo et al. Recombinant cholera toxin B subunit acts as an adjuvant for the mucosal and systemic responses of mice to mucosally co-administered bovine serum albumin
HRP20201265T1 (hr) Postupci liječenja i sprječavanja infekcija sa staphilococcus aureus i povezanih stanja
JP2017214397A5 (enExample)
Pérez et al. New vaccines require potent adjuvants like AFPL1 and AFCo1
Guo et al. Therapeutic protection against H. pylori infection in Mongolian gerbils by oral immunization with a tetravalent epitope-based vaccine with polysaccharide adjuvant
AU2014277027B2 (en) Immunogenic composition for use in therapy
US10576140B2 (en) Cholera toxin chimera and its use as a staph vaccine
Joshi et al. Comparative immunogenicity and protective efficacy of different preparations of outer membrane proteins of Pasteurella multocida (B: 2) in a mouse model
WO2010040847A3 (en) Recombinant protein bodies as immunogen-specific adjuvants
JP5237259B2 (ja) 過剰産生黄色ブドウ球菌株の５型および８型莢膜多糖
López-Matas et al. Depigmented allergoids reveal new epitopes with capacity to induce IgG blocking antibodies
Ma et al. Als3‐Th‐cell‐epitopes plus the novel combined adjuvants of CpG, MDP, and FIA synergistically enhanced the immune response of recombinant TRAP derived from Staphylococcus aureus in mice
Arlian et al. Mucosal immunization with a Staphylococcus aureus IsdA-cholera toxin A2/B chimera induces antigen-specific Th2-type responses in mice
US8911748B2 (en) Cholera toxin chimera and its use as a staph vaccine
JP2016525507A5 (enExample)
Yang et al. Protection against Staphylococcus aureus and tetanus infections by a combined vaccine containing SasA and TeNT-Hc in mice
Amin et al. Novel Klebsiella pneumoniae and Pseudomonas aeruginosa MAPS vaccine combining O polysaccharides and pathogen-specific proteins
AU2015359503B2 (en) Method of treatment
CN103212060B (zh) 蛋白及其组合物与在制备预防、诊断或治疗ehec感染产品中的应用
Sumit Joshi et al. Comparative immunogenicity and protective efficacy of different preparations of outer membrane proteins of Pasteurella multocida (B: 2) in a mouse model.
RU2008131066A (ru) Фармацевтическая композиция, содержащая белок nma0939
Joshi et al. Poredbena imunogenost i zaštitna učinkovitost različitih pripravaka proteina vanjske membrane bakterije Pasteurella multocida (B: 2) na mišjem modelu.
Misra Development of a Cholera Toxin CTA 2/B Based Staphylococcus aureus Vaccine to Prevent Bovine Mastitis
WO2004043286A3 (en) Use of rmlt as a marker antigen for vaccines and as a synergistic adjuvant with amphigen

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20141016